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1. Introduction 
The prognosis of early-stage endometrial cancer is favorable, even when treated using 
surgery alone, whereas recurrent cases or advanced cases (stage III or IV) with progression 
beyond the uterus have a poor prognosis1), and therapy for such cancers is still in the 
exploratory stages. Stage I and II cases are sometimes treated with adjuvant therapy to 
prevent recurrence after surgical therapy; however, the treatment options for these cases 
remain controversial. The boundaries encompassing intermediate risk cases may be 
approached in several ways, and it would be difficult to say that any consensus has been 
reached, although examples often include stage IIB (FIGO stage 1988) and higher, stage IC 
endometrioid adenocarcinoma, all grade 3 (poorly-differentiated) endometrioid 
adenocarcinoma, non-endometrioid adenocarcinoma, and marked lymphovascular space 
invasion2,3). Radiation therapy and chemotherapy are the two primary modalities of 
postoperative adjuvant therapy for patients with these types of endometrial cancer 
characterized by a poor prognosis or a risk of recurrence. In this chapter, we first refer 
briefly to adjuvant radiotherapy. 
2. Radiation therapy for endometrial cancer 
In Europe and the US, the postoperative therapy most commonly used for intermediate-risk 
patients with advanced endometrial cancer or early-stage cancer who are at risk of 
recurrence is mainly radiation therapy4). In Japan, on the other hand, chemotherapy is often 
chosen as a postoperative therapy, and radiation therapy is performed only for limited 
cases. Radiation therapy is indicated as an option for initial treatment only when surgery 
would be difficult to perform from a practical perspective, such as in advanced cases that 
are considered inoperable, and in cases where surgery is considered a high-risk procedure 
because of serious complications, obesity, or other reasons5). The following types of 
radiation therapy can be used for endometrial cancer following a hysterectomy. (1)Vaginal 
brachytherapy: A radioactive source for brachytherapy is inserted into the vagina and left 
there for two to three days. (2)External-beam radiation therapy (EBRT): Tumors are exposed 
to radiation from outside the body. 
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There are two kinds of EBRT: whole abdominal irradiation (WAI) and whole pelvic 
irradiation (WPI). WAI or WPI is usually carried out as postoperative radiation therapy and 
is sometimes accompanied by vaginal brachytherapy. 
The effects of postoperative radiation therapy on intermediate-risk cases of early-stage 
endometrial cancer have been studied in comparison with groups observed over time in the 
absence of postoperative treatment in NRH6), PORTEC7), GOG-998). Although these reports are 
from different regions, they all showed the same results. Specifically, the effect in suppressing 
local recurrence was significantly better in the radiation therapy groups, but radiation did not 
significantly prolong progression-free survival (PFS) or overall survival (OS). 
A study on the effects of postoperative (adjuvant) EBRT on outcome in patients with early-
stage endometrial cancer was recently reported in The Lancet9). Out of 905 patients with 
early-stage cancer in seven countries that had been enrolled in the ASTEC and EN.5 studies, 
intermediate to high-risk patients who had undergone surgery for endometrial cancer were 
randomly assigned to an observation or an EBRT group. The risk of developing distant 
metastasis based on the PORTEC and GOG99 data, where a high risk was defined as “all 
papillary serous and clear cell subtypes, all other subtypes in IC (grade 3) and IIA (grade 3), 
and all patients with stage IIB”, and intermediate risk was defined as “subtypes other than 
papillary serous and clear cell histology within stage IA and IB (grade 3) and stage IC and 
IIA (grades 1 and 2).” The results of an analysis revealed that, after 58 months of follow up, 
the hazard ratio (HR) for death was 1.05 (95% CI, 0.75 to 1.48; P = 0.77) in 68 out of 453 
subjects in the group observed over time and in 67 out of 452 subjects in the EBRT group, 
indicating no difference in OS. There was also no significant difference in terms of 
recurrence-free survival (RFS), with a HR of 0.93 (95% CI, 0.66 to 1.31; P = 0.68). The 
incidence of distant recurrence was also the same (8% in the observation group and 9% in 
the EBRT group), but the HR of 0.46 (95% CI, 0.24 to 0.89; P = 0.02) for vaginal or pelvic 
initial recurrence indicated that local recurrence was suppressed in the EBRT group. 
However, since these numbers do not include cases of distant metastasis or simultaneous 
local recurrence/distant metastasis, which account for 65% of recurrences, the overall 
outcome was not considered to have improved. The development of acute toxicity was also 
higher in the EBRT group, with a rate of 43% compared to the rate of 27% in the group 
without radiation therapy. 
A meta-analysis9) of 2011 cases comprising the PORTEC and GOG99 data was performed in 
addition to the above ASTEC and EN.5 data. The HR for OS was 1.04 (95% CI, 0.84 to 1.29; P 
= 0.38), indicating no significant differences depending on whether or not adjuvant EBRT 
was performed. A sub-analysis divided the patients into what the authors termed 
intermediate risk and high risk also revealed no significant differences in OS between the 
ASTEC+EN.5 and the ASTEC+EN.5+PORTEC+GOG99 data. 
Because adjuvant EBRT thus failed to improve survival and also resulted in adverse effects 
in early-stage endometrial cancer patients who had a risk of recurrence, the authors 
concluded that such treatment could not be recommended for patients with early-stage 
endometrial cancer. 
3. Chemotherapy for advanced or recurrent endometrial cancer 
Although adjuvant EBRT can be expected to be effective to a certain extent for advanced or 
recurrent endometrial cancer, chemotherapy with anti-tumor agents is also being 
additionally performed in Europe and the US. After many changes in regimens, AP therapy 
www.intechopen.com
 Adjuvant Chemotherapy for Endometrial Cancer 
 
169 
(combining doxorubicin and cisplatin) is currently the standard therapy. The changes in 
regimens are summarized below. 
From the 1970s to the 1980s, doxorubicin monotherapy was reported to result in a response 
rate of 20% to 42%10), and a good response rate of 45% to 60% was reported in a subsequent 
phase II study combining cisplatin with doxorubicin11). These two drugs therefore came to 
be positioned as key drugs in chemotherapy for endometrial cancer. In the 1990s, the 
Gynecologic Oncology Group (GOG) in the US and the European Organization for Research 
and Treatment of Cancer (EORTC) conducted phase III randomized comparative studies on 
“doxorubicin vs. doxorubicin + cisplatin (AP therapy)” in both the GOG10712) and 
EORTC5587213) trials, respectively, and the response rates of 25% vs. 42% in the GOG107 
study and 43% vs. 17% in the EORTC55872 study demonstrated the efficacy of AP therapy. 
Although no significant differences in OS were found in the GOG-107 study, AP therapy 
was shown to be superior in the EORTC55872 study. On the other hand, CAP 
(cyclophosphamide + doxorubicin + cisplatin) therapy is also being used for endometrial 
cancer in Japan, where chemotherapy is more often performed as a postoperative therapy5). 
However, cyclophosphamide was not found to result in significant differences in the 
response rate in phase II studies of CAP therapy and AP therapy14), while the GOG48 study 
on “doxorubicin vs. doxorubicin + cyclophosphamide (AC therapy)” also revealed no 
significant differences in the response rate, response period, or OS, thus contradicting the 
usefulness of concomitant cyclophosphamide for endometrial cancer15);AP therapy has come 
to be acknowledged as the standard chemotherapy for endometrial cancer in Japan as well. 
Radiation therapy and chemotherapy are thus the primary modalities of therapy that should 
be used after surgery for endometrial cancer. However, the following three questions still 
need to be answered: 
1. Which is more effective for advanced or recurrent cancer: radiation therapy or 
chemotherapy? 
2. Radiation therapy has been shown to be ineffective for early-stage patients classified as 
being at risk for recurrence, but is chemotherapy effective? 
3. Alternatively, is the combination of radiation therapy and chemotherapy effective for 
early-stage patients classified as being at risk for recurrence? 
4. Radiation therapy vs. chemotherapy as adjuvant therapy for endometrial 
cancer 
Three randomized studies have compared radiation therapy and chemotherapy as adjuvant 
therapies for endometrial cancer (Table 1). 
4.1 GOG122 
The GOG12216), reported in the US in 2006, was a randomized study comparing WAI and 
AP therapy as first-line therapies for stage III and IV cases with residual tumors no greater 
than 2 cm after surgery. The HR for progression adjusted for stage was 0.71, favoring AP 
therapy (95% CI, 0.55 to 0.91; P < 0.01). At 60 months, 50% of the patients receiving AP were 
predicted to be alive and disease-free after adjustments for stage, compared with 38% of 
patients receiving WAI. The stage-adjusted death HR was 0.68 (95% CI, 0.52 to 0.89; P < 
0.01), favoring AP therapy. Moreover, at 60 months and after adjustments for stage, 55% of 
the AP patients were predicted to be alive, compared with 42% of the WAI patients. The PFS 
and OS were both significantly higher in the AP arm, but greater acute toxicity was seen in the  
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a: significantly better 
Table 1. Randomized trials comparing radiation therapy and chemotherapy as an adjuvant 
therapy for endometrial cancer. 
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AP arm. Treatment probably contributed to the deaths of 8 patients (4%) in the AP arm and 5 
patients (2%) in the WAI arm, indicating that AP therapy was associated with a somewhat 
stronger toxicity. However, in view of the survival data, AP chemotherapy appeared to be 
better than radiation therapy as a first-line postoperative therapy for advanced endometrial 
cancer. This was the first trial to reveal the positive effects of chemotherapy over radiation 
therapy. A subgroup analysis revealed that significantly lower HRs regarding OS were 
recognized in patients younger than 60 years old, cases with microscopic residual tumors, 
cases with a pathological subtype of endometrioid adenocarcinoma, and stage III cases. After 
the results of this study were reported, chemotherapy tended to be more often incorporated 
into adjuvant therapy for endometrial cancer.  
4.2 Italian study 
Maggi R et al. 17) reported a multicenter randomized trial comparing five courses of 
adjuvant chemotherapy with CAP (cyclophosphamide, 600 mg/m2; doxorubicin, 45 mg/m2; 
and cisplatin, 50 mg/m2) and external radiation therapy (45 Gy) for mainly high-risk 
endometrial cancer patients, including stage IC grade 3, stage IIA to IIB grade 3 with more 
than 50% myometrial invasion (stage I/II: 36%), and also stage III disease. The pathological 
subtype was restricted to endometrioid type. Selective pelvic and paraaortic node sampling 
were performed; however, the percentage of patients undergoing a lymphadenectomy was 
not stated. More than 60% of the cases were stage III and had a high risk of recurrence. The 
3-, 5-, and 7-year OS rates were 78%, 69% and 62% in the RT group and 76%, 66% and 62% 
in the CT group. The 3-, 5-, and 7-year PFS rates were 69%, 63%, and 56% and 68%, 63%, and 
60%, respectively. This study revealed no significant differences in the OS or the PFS. 
Radiation therapy delayed local relapses, and CT delayed distant metastases. 
4.3 JGOG2033 
In 2008, the Japanese Gynecologic Oncology Group (JGOG) published a paper18) about a 
randomized phase III trial (JGOG2033) comparing adjuvant chemotherapy with 
cyclophosphamide (333 mg/m2), doxorubicin (40 mg/m2), and cisplatin (50 mg/m2) (CAP) 
administered every four weeks for three or more cycles with radiotherapy administered 
using pelvic EBRT (PRT) at 50 Gy in 385 patients with endometrioid adenocarcinoma and 
myometrial invasion deeper than 50%, myometrial invasion, most of whom had an 
intermediate -risk but a small proportion of whom had a high -risk of recurrence after the 
initial operation for endometrial cancer. No statistically significant differences in the PFS or 
OS were recognized between the patient groups treated with the two modalities. However, 
in the high intermediate-risk (HIR) group consisting of (1) patients with stage IC disease 
who were over 70 years of age and/or had G3 endometrioid adenocarcinoma and (2) 
patients with stage II or IIIA disease (positive cytology), the CAP treatment was associated 
with a significantly higher PFS rate (83.8% vs. 66.2%) as well as a higher OS rate (89.7% vs. 
73.6%). Adjuvant chemotherapy was emphasized as being a useful alternative to 
radiotherapy for patients with intermediate-risk endometrial cancer. 
In this study, a pelvic lymphadenectomy was performed in 96% of the cases and a 
paraaortic lymphadenectomy was performed in 29% of the cases; furthermore, the ratio of 
stage I or II cases was higher (75% vs. 35%) and the ratio of grade 3 tumors was lower (14% 
vs. 56%). Most of the cases in JGOG2033 study had an intermediate risk, while most of the 
cases in the Italian study17) had a high risk. Although both of these studies used the CAP 
regimen, the doses of cyclophosphamide and doxorubicin were lower and the number of 
chemotherapy cycles was fewer in the JGOG2033 study (Table 2). In fact, the incidence of  
www.intechopen.com
 Cancer of the Uterine Endometrium – Advances and Controversies 
 
172 
 
a: recurrent tumor 
Table 2. Randomized trials comparing chemotherapy regimens as an adjuvant therapy for 
endometrial cancer. 
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G3/4 adverse effects was lower in the JGOG2033 study. The CAP regimen in the JGOG2033 
study, therefore, represented a more modest therapy than that used in the Italian study. 
Nevertheless, the 5-year PFS rate and OS rate of the high-intermediate risk (HIR) subgroup 
of the JGOG2033 study were significantly improved by this modest CAP regimen. This 
means that the cases in the high-intermediate risk (HIR) subgroup of the JGOG2033 study 
may be good candidates for answering the question, “Which patients with endometrial 
cancer may benefit from adjuvant chemotherapy?” To answer this question definitively, 
further evidence is needed from randomized studies investigating the efficacy of adjuvant 
chemotherapy designed for patients with intermediate- or high-risk endometrial cancer. The 
modest adjuvant chemotherapy regimen of CAP was superior to pelvic radiotherapy in HIR 
patients, as defined above; however, this chemotherapy did not have a sufficient efficacy to 
improve the prognosis of patients with stage III advanced endometrial cancer. 
The Italian study17) revealed no significant differences in the PFS or OS rates among high-
risk patients even when a higher-dose CAP regimen was used. The dose of doxorubicin was 
60 mg/m2 in the GOG122 study16), 45 mg/m2 in the Italian study, and 40 mg/m2 in the 
JGOG2033 study18). 
4.4 What is the best adjuvant chemotherapy for endometrial cancer? 
Then, what is the best adjuvant chemotherapy for endometrial cancer? First, let me look 
back to some studies for advanced or recurrent endometrial cancer. 
The response rates to paclitaxel in phase II studies for advanced or recurrent endometrial 
cancer were reported to be 37.5%19) and 30.4%20) in 1996 and 2004, respectively, and the 
response rates to docetaxel in phase II studies for advanced or recurrent endometrial cancer 
were reported to be 33%21) and 31.3%22) in 2002 and 2005, respectively. These numbers are 
comparable to the response rates obtained with doxorubicin alone. 
In the GOG163 phase III randomized study23) of AP vs. concomitant doxorubicin + 
paclitaxel (AT) + G-CSF reported in 2004 on the effects of combining a taxane with 
doxorubicin or cisplatin, the response rates of 40% vs. 43% revealed no significant 
differences when compared with the concomitant use of cisplatin, and the median OS was 
12.6 months vs.13.6 months, with a HR of 1.00. Furthermore, AT therapy had more 
disadvantages, such as the need for G-CSF support, compared with AP therapy, and no 
advantage was found in switching from cisplatin to paclitaxel as the concomitant drug to 
be used with doxorubicin. 
On the other hand, the GOG177 phase III randomized study24) of AP vs. concomitant 
paclitaxel + doxorubicin + cisplatin (TAP) + G-CSF reported in the same year (2004) showed 
that the results of TAP therapy were superior, based on response rates of 34% vs. 57%. The 
median PFS (8.3 months vs. 5.3 months) and the median OS (15.3 months vs. 12.3 months) 
were significantly improved in the TAP group. However, in the TAP arm, the incidence of 
neurotoxicity was significantly higher, and congestive heart failure or treatment-related 
deaths occurred. Compliance was therefore considered to be poor in view of the toxicity, 
and TAP therapy has not widely replaced AP as a standard therapy in clinical practice. 
Based on the results of the GOG163 study, it seemed that the next steps should be to study the 
significance of replacing doxorubicin, which has been considered a key drug for a long time, 
with a taxane and to study which of the two platinum agents should be used. There was thus a 
need to first study whether or not a regimen combining two agents (taxane + platinum agent) 
would be better than AP. As there are two taxanes and two platinum agents, whether these 
regimens or AP therapy would be more effective was investigated in Japan. 
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Out of the various combinations of the two taxanes and two platinum agents, i.e., TC 
(paclitaxel + carboplatin), DP (docetaxel + cisplatin), DC (docetaxel + carboplatin), and TP 
(paclitaxel + cisplatin), the efficacy and safety of the TC, DP, and DC regimens were first 
compared in JGOG2041, a phase II randomized study25) (Table 2). TP therapy had already 
been eliminated, as the results of clinical trials for ovarian cancer revealed a strong 
neurotoxicity, and a shift from TP to TC therapy had occurred26-28). The results revealed the 
response rates of the three regimens to be in no way inferior to AP therapy, and the toxicity 
was also within an acceptable range25). 
Based on the results of the JGOG2041 study, a phase III randomized study (JGOG2043) was 
conducted to compare AP therapy with chemotherapy combining platinum and taxanes in 
groups with a high risk for the recurrence of endometrial cancer. The results of the 
JGOG2041 study revealed the response rate of DC therapy (48%) to be somewhat lower, 
although not significantly, than that of TC therapy (60%) and DP therapy (52%), and TC and 
DP therapy were therefore selected for comparison with AP therapy in the JGOG2043 study. 
The groups with a high risk for the recurrence of endometrial cancer in the JGOG2043 study 
included advanced cases with residual tumors of no greater than 2 cm, and stage I and II 
cases with invasion to more than half of the myometrium and histological grade 2 or 3 
(including serous or clear cell adenocarcinoma), thus allowing the effects on advanced cases 
and intermediate risk cases to be analyzed separately using sub-analyses. Enrollment in this 
study was closed at the end of 2010. 
In the phase II study, the TC response rate was 60% and the compliance was high (90%). The 
response rate of TC is therefore being compared with that of TAP (which had the highest 
response rate in the GOG177 study but had problems in compliance) in patients with 
advanced or recurrent cancer. The results of the JGOG2041 study, in conjunction with the 
results of a comparison of the efficacies of TC, DP, and AP in the JGOG2043 study, should 
prove to be useful for research on the most effective and appropriate chemotherapy 
regimens. Randomized studies, such as GOG 209 (TAP vs. TC for advanced or recurrent 
disease) and JGOG 2043 (AP vs. TC vs. DP for adjuvant therapy) are now underway. The TC 
regimen is widely used both in practical treatment and in research trials for endometrial 
cancer, based on the promising efficacies reported by various phase II studies, although no 
evidence of a phase III trial level that certifies TC as a truly standard regimen for 
endometrial cancer has been obtained. 
Chemotherapy has been the mainstream treatment in Japan, but postoperative therapy in 
Europe is now shifting from the formerly preferred radiation therapy alone to radiation 
therapy plus chemotherapy. In the US as well, the GOG194 study (closed) for WAI vs. WAI 
followed by paclitaxel + doxorubicin + cisplatin (TAP therapy) is being conducted to test the 
effects of combining chemotherapy with radiation therapy as a postoperative treatment 
regimen for intermediate-risk or high-risk cases. 
5. Comparison of radiation therapy alone and the combination of radiation 
therapy and chemotherapy  
Several randomized studies have compared radiation therapy alone and the combination 
of radiation therapy and chemotherapy as an adjuvant therapy for endometrial cancer 
(Table 3). 
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a: sampling of PLN or PAN was not required. 
b: significantly better 
c: 1) G2/3 with LVSI and outer-third myometrial invasion, 2) age of 50 years or greater in addition to 
any two factors listed above, or 3) age of 70 years or greater with any risk factor listed above. 
Table 3. Randomized trials comparing radiation therapy with combination of radiation 
therapy and chemotherapy as an adjuvant therapy for endometrial cancer. 
www.intechopen.com
 Adjuvant Chemotherapy for Endometrial Cancer 
 
177 
5.1 GOG34 
This study was the first randomized trial to compare radiation alone and radiation followed 
by chemotherapy29). The subjects were comprised of patients with clinical stage I or II 
(occult) disease in whom surgical-pathologic evaluation had revealed one or more risk 
factors for recurrence: a greater than 50% myometrial invasion, pelvic or aortic node 
metastasis, cervical involvement, or adnexal metastases. The patients received 50-Gy EBRT 
with or without paraaortic radiation and were then randomized into two arms: no further 
therapy or additional doxorubicin (45 – 60 mg/m2) every three weeks to a maximum 
cumulative dose of 500 mg/m2. No statistically significant difference in the OS or PFS was 
observed between the two arms. Unfortunately, because of protocol violations, the small 
sample size, and the number of patients lost to follow-up, this study was unable to 
determine what effect the use of doxorubicin as an adjuvant therapy had on recurrence, 
progression, and survival. 
5.2 Finnish study 
For the Finnish study30), surgically staged IA-B G3 cases or stage IC-IIIA G1-3 cases were 
enrolled and randomized to receive pelvic EBRT alone (28 Gy x 2 cycles) or a unique 
combination of alternating EBRT and chemotherapy, namely, a first cycle of CEP 
(cyclophosphamide 500 mg/m2; epirubicin, 60 mg/m2; and cisplatin, 50 mg/m2) followed 
by a first cycle of EBRT (28 Gy), a second cycle of CEP, a second cycle of EBRT (28 Gy), and 
finally a third cycle of CEP. However, this study failed to reveal an improvement in the OS 
or PFS by the addition of chemotherapy to radiation therapy. Moreover, adverse events such 
as severe bowel obstruction requiring surgery tended to occur more frequently in the 
combined treatment arm. 
5.3 GOG 184 
For the GOG184 study31), surgically staged III or IV cases were enrolled and treated with 
volume-directed irradiation of the pelvic/para-aortic lymph nodes. The patients were 
subsequently randomized to compare the recurrence-free survival (RFS) and toxicity between 
two chemotherapy regimens. Treatment was randomized between six cycles of cisplatin (50 
mg/m2) and doxorubicin (45 mg/m2) with or without paclitaxel (160 mg/m2). The accrual of 
stage IV patients was completed in June, 2003. Approximately 80% of the subjects completed 
six cycles of chemotherapy. Three deaths resulted from bowel complications, and one death 
was caused by renal failure. Hematologic adverse events, sensory neuropathy, and myalgia, 
were more frequent and severe in the paclitaxel arm (P < 0.01). The percentage of patients alive 
and recurrence-free at 36 months was 62% for RT + AP vs. 64% for RT + TAP. The hazard of 
recurrence or death relative to the RT + AP arm and stratified according to stage was 0.90 (95% 
CI, 0.69 to 1.17; P = 0.21). However, in a subgroup analysis, RT + TAP was associated with a 
50% reduction in the risk of recurrence or death among patients with gross residual disease 
(95% CI, 0.26 to 0.92). This study showed that the addition of paclitaxel to cisplatin and 
doxorubicin following surgery and radiation was not associated with a significant 
improvement in RFS but was associated with increased toxicity. 
5.4 NSGO 9501/ EORTC 55991 study and MaNGO ILIADE III study 
Hogberg et al. reported a paper32), presenting two randomized clinical trials (NSGO EC9501 
/EORTC55991 and MaNGO ILIADEIII). The former study was reported at the ASCO 2007 
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meeting33). These two studies were undertaken to clarify whether the sequential combination 
of chemotherapy and radiotherapy improves the PFS in high-risk subjects with endometrial 
cancer. These studies had similar designs; however, some differences existed regarding the 
distribution of stages and the rates of pelvic or paraaortic lymphadenectomy. Most of the 
enrolled cases were stage I in the former study, while all the cases were stage II or III in the 
latter study; in addition, the rate of pelvic or paraaortic lymphadenectomy was higher in the 
ILIADEIII study. In total, patients (n = 540) with surgically resected endometrial cancer stage I 
– III and with no residual tumor or prognostic factors implying a high -risk were randomly 
allocated to an adjuvant radiotherapy group with or without sequential chemotherapy. 
In the NSGO/EORTC study, patients with stage I, II, IIIA (positive peritoneal fluid cytology 
only), or IIIC (positive pelvic lymph nodes only) diseases were enrolled. The chemotherapy 
modalities included AP (doxorubicin, 50 mg/m2 + cisplatin, 50 mg/m2; 83%), EP 
(epirubicin, 75 mg/m2; 4%), TEC (paclitaxel, 175 mg/m2 + epirubicin, 60 mg/m2 + 
carboplatin, AUC 5; 3%), and TC (paclitaxel, 175 mg/m2, carboplatin, AUC 5 – 6; 10%). The 
radiation arm consisted of pelvic EBRT (44 Gy) with or without brachytherapy. The 
combined modality treatment was associated with a 36% reduction in the risk of relapse or 
death (HR, 0.64; 95% CI, 0.41 – 0.99; P = 0.04); two-sided tests were used. In the MaNGO 
ILIADEIII study, only the AP therapy was used as a chemotherapy regimen. The results 
from the MaNGO ILIADEIII study pointed in the same direction (HR, 0.61) as those of the 
NSGO/EORTC study, but were not significant. In both studies, adverse effects were more 
severe in the combined modality group. 
In the combined analysis, the estimate of the risk for relapse or death was similar but with 
narrower confidence limits (HR, 0.63; 95% CI, 0.44 – 0.89; P = 0.009). Neither study showed 
significant differences in the OS. In the combined analysis, the OS approached statistical 
significance (HR, 0.69; 95% CI, 0.46 – 1.03; P = 0.07) and cancer-specific survival (CSS) was 
significant (HR, 0.55; 95% CI, 0.35 – 0.88; P = 0.01). Thus, the addition of adjuvant 
chemotherapy to radiation improved the PFS and CSS in surgically treated endometrial 
cancer patients with no residual tumor and a high-risk profile. Regarding the pathological 
subtypes, combined therapy offered a superior benefit to patients with endometrioid type 
and grade 1 or 2 diseases, but not to patients with serous or clear cell types and grade 3 
diseases. Several remaining questions need to be further investigated in future trials. 
6. Ongoing trials comparing radiation therapy alone and radiation therapy 
plus chemotherapy 
At present, there are several ongoing studies comparing radiation therapy alone and 
radiation plus chemotherapy (Table 3). The RTOG-GOG9905 study finished accrual in 2004; 
however, its results have not yet been presented. Accrual for the PORTECIII and GOG249 
trials is ongoing. These three trials are phase III randomized trials comparing a radiation 
alone group and a combined radiation and chemotherapy group. Two of them are 
examining concurrent chemoradiotherapy followed by four cycles of TC, and the third trial 
is examining brachytherapy followed by three cycles of TC.  
7. Conclusions 
As described above, many problems regarding adjuvant therapy for endometrial cancer 
remain. (1) Which patients receive the highest benefit from adjuvant therapy? (2) Is there a 
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definite consensus regarding the criteria for grouping patients according to the risk of 
recurrence? (3) Which chemotherapy regimen should be certified as the gold standard 
regimen for adjuvant therapy based on the results of phase III randomized trials? (4) Which 
combination of radiation therapy and chemotherapy is best? To answer these questions, 
before designing a trial concept, a worldwide consensus on the criteria for risk groups needs 
to first be obtained. In addition, to interpret the results of various adjuvant therapy trials, 
careful attention to the kind of surgery that the patients have received and the percentages 
of grade 3 endometrioid adenocarcinoma and aggressive pathological subtypes (serous, 
clear cell, undifferentiated, and so on) is needed. In this review, as shown in Tables 1, 2, and 
3, we have collected information regarding the percentages of pelvic lymphadenectomy, 
paraaortic lymphadenectomy, grade 3 endometrioid adenocarcinoma or aggressive 
pathological subtypes, and informations about surgical stage distribution, treatment 
compliance, and adverse effects. Before arguing the results of clinical trials, sufficient 
information regarding the patient conditions after surgery and just before receiving 
adjuvant therapy is needed. For example, some trials with low percentages of pelvic or 
paraaortic lymphadenectomy, trials with high percentages of G3 or aggressive pathological 
subtypes, and trials with high percentages of advanced stage patients tend to favor 
chemotherapy, since these patient groups tend to have higher possibilities of 
micrometastases that cannot be identified using imaging. 
The results of ongoing studies, such as GOG0237 (TAP vs. TC, advanced or recurrent 
disease, phase III) and JGOG2043 (AP vs. DP vs. TC, adjuvant, phase III) may provide 
important information regarding question (3) above, and the results of the RTOG-GOG9905, 
PORTECIII, and GOG249 studies may help to answer question (4). Further studies are 
needed to resolve question (1). 
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